Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Esperion Therapeutics, Inc. (ESPR : NSDQ)

• Company Description    Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol). Number of Employees: 294

• Price / Volume Information    Yesterday's Closing Price: $3.13 Daily Weekly Monthly 20 Day Moving Average: 21,262,434 shares Shares Outstanding: 257.43 (millions) Market Capitalization: $805.76 (millions) Beta: 0.91 52 Week High: $4.18 52 Week Low: $0.76 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 63.87% 55.87% 12 Week -6.85% -13.88% Year To Date -15.40% -22.23%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3891 RANCHERO DRIVE SUITE 150 - ANN ARBOR,MI 48108 USA ph: 734-887-3903 fax: - investorrelations@esperion.com http://www.esperion.com

• General Corporate Information    Officers Sheldon L. Koenig - Chief Executive Officer; President and Director Benjamin Halladay - Chief Financial Officer J. Martin Carroll - Director Seth H.Z. Fischer - Director Robert E. Hoffman - Director Peer Information Esperion Therapeutics, Inc. (GSAC) Esperion Therapeutics, Inc. (CASIF) Esperion Therapeutics, Inc. (ALCD.) Esperion Therapeutics, Inc. (OMNN) Esperion Therapeutics, Inc. (CGPI.) Esperion Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 29664W105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 257.43 Most Recent Split Date: (:1) Beta: 0.91 Market Capitalization: $805.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 26.76% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: 68.04 Trailing 12 Months: - PEG Ratio: 2.54 Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 1.93 EPS Growth vs. Year Ago Period: 52.38% vs. Previous Quarter: -145.45% Sales Growth vs. Year Ago Period: 23.25% vs. Previous Quarter: -52.45% ROE 03/31/26 - -0.14 12/31/25 - - 09/30/25 - - ROA 03/31/26 - 0.12 12/31/25 - -3.93 09/30/25 - -27.91 Current Ratio 03/31/26 - 1.53 12/31/25 - 1.54 09/30/25 - 1.00 Quick Ratio 03/31/26 - 1.18 12/31/25 - 1.19 09/30/25 - 0.70 Operating Margin 03/31/26 - 0.12 12/31/25 - -3.66 09/30/25 - -31.67 Net Margin 03/31/26 - 0.12 12/31/25 - -3.66 09/30/25 - -32.22 Pre-Tax Margin 03/31/26 - -1.33 12/31/25 - -5.17 09/30/25 - -34.84 Book Value 03/31/26 - -1.20 12/31/25 - -1.26 09/30/25 - -2.24 Inventory Turnover 03/31/26 - 1.22 12/31/25 - 1.21 09/30/25 - 1.22 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©